Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
Revenue Growth %: +23.1%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +23.1%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43.4 million versus the consensus estimate of $25.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- FirstCash to acquire UK pawn operator Ramsdens for £206 million
- Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
